Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed July 28, 2026. Open the filing →
- Filed
- Jul 28, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-087545
FAQ
- What is Kiniksa Pharmaceuticals International, plc's D&A?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported D&A of $472K in Q2 2026.
- How has Kiniksa Pharmaceuticals International, plc's D&A changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's D&A increased by 31.8% year-over-year, from $358K to $472K.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's D&A?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's D&A has grown at a -9.9% compound annual growth rate (CAGR), from $2.36M to $1.55M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Kiniksa Pharmaceuticals International, plc's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude